Mandelamide Heterocyclic Compounds for Selective S1P1 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for S1P1 agonists that are selective over S1P3 to avoid the undesirable cardiovascular effects associated with non-selective S1P receptor modulation, such as bradycardia and hypertension, while maintaining therapeutic efficacy in autoimmune and vascular diseases.
Innovation Solution
Development of mandelamide heterocyclic compounds that act as selective S1P1 agonists, reducing side effects by minimizing S1P3 activity, with specific structures defined by Formula (I) and its stereoisomers, salts, and prodrugs, which are used in pharmaceutical compositions for treating autoimmune and vascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective S1P receptor modulation is used, then immunosuppressive efficacy is improved, but cardiovascular side effects worsen
Solution Approach 1:
The patent applies segmentation by designing compounds that selectively target specific S1P receptor subtypes (S1P1, S1P2, S1P3) rather than all S1P receptors. This is achieved through structural modifications to the mandelamide heterocyclic core, creating distinct binding profiles for different receptor isoforms, thereby achieving immunosuppression through S1P1 modulation while avoiding S1P3-mediated cardiovascular effects
Solution Approach 2:
The patent implements local quality by introducing specific substituent patterns at defined positions on the heterocyclic ring system. These localized structural changes (e.g., substituents at R1, R2, R3 positions) confer selective affinity for particular S1P receptor subtypes, allowing the molecule to exhibit different functional qualities at different receptor targets
2Reliability
If S1P1 receptor agonism is increased, then lymphocyte trafficking control is improved, but S1P3-mediated toxicity worsens
Solution Approach 1:
The patent extracts the desired therapeutic effect (S1P1-mediated lymphocyte trafficking control) from the harmful effects (S1P3-mediated acute toxicity) by designing compounds with selective S1P1 agonism. The molecular structure is optimized to maintain affinity for S1P1 while reducing affinity for S1P3, effectively separating the beneficial immunomodulatory effects from the detrimental cardiovascular effects
3Object-affected harmful factors
If compound selectivity for S1P1 over S1P3 is increased, then side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying structural parameters of the mandelamide heterocyclic core (substituent types, positions, and configurations) to optimize the selectivity profile. By adjusting these molecular parameters, the compounds achieve enhanced S1P1 over S1P3 selectivity while maintaining reasonable structural complexity for drug development
Data Source
AI summary
Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.